Digital pathology market pushing integration

Pathology is moving from single tools to bundled software-and-scanner stacks, as vendors pair digital slide capture with remote review and image analysis for hospitals and reference labs. (cap.org) In digital pathology, a scanner turns a glass tissue slide into a high-resolution file that a pathologist can review on a screen instead of through a microscope. The United States Food and Drug Administration has already cleared systems such as Philips IntelliSite Pathology Solution for primary diagnosis, and the College of American Pathologists says laboratories still need to validate whole-slide imaging before clinical use. (fda.gov) (cap.org) Telepathology adds the network layer: once a slide is digitized, a pathologist in another building or another state can review the case. The Centers for Medicare and Medicaid Services said on May 11, 2023 that pathologists and other laboratory personnel may continue to review digital materials remotely without a separate Clinical Laboratory Improvement Amendments certificate, subject to the primary laboratory’s certification and other federal rules. (cms.gov) (cap.org) The commercial push now is to sell those pieces together. Philips says its digital pathology offering includes whole-slide scanners, image management software, and implementation services, while Leica Biosystems said in 2024 that its Aperio GT 450 DX received Food and Drug Administration clearance with Digital Imaging and Communications in Medicine support, a standard file format meant to make systems talk to each other more easily. (philips.com) (leicabiosystems.com) Software vendors are also widening compatibility with multiple scanners and file types. Paige said on January 14, 2025 that its FullFocus viewer received Food and Drug Administration 510(k) clearance for use with Leica Aperio GT 450 DX and Hamamatsu NanoZoomer S360MD systems, after earlier clearance with the Philips IntelliSite Pathology Solution Ultra Fast Scanner 2. (paige.ai) (accessdata.fda.gov) That matters to laboratories because pathology is not just image viewing; it is case management, sign-out, quality checks, storage, and consultation across sites. The College of American Pathologists’ 2024 topic center and guideline update frame digital pathology as an operational workflow change, not just a hardware purchase. (cap.org 1) (cap.org 2) Artificial intelligence is being added on top of that stack, usually as software that flags patterns or helps manage images rather than replacing the pathologist. Food and Drug Administration records show Paige’s cleared FullFocus product is intended for viewing and management of scanned surgical pathology images, underscoring that regulated products in this space often start with workflow and review functions before broader diagnostic claims. (accessdata.fda.gov) (510k.innolitics.com) Market researchers are putting growth numbers behind the integration story, though their forecasts vary. Grand View Research said the global digital pathology market could reach $1.73 billion by 2030, while Global Market Insights put the market at $1.1 billion in 2024 and projected $3.8 billion by 2034. (marketresearch.com) (gminsights.com) The result is a market where the scanner, viewer, archive, remote access, and artificial intelligence tools are increasingly sold as one purchasing decision. For hospitals and large reference labs, the bet is less about buying a digital microscope and more about choosing the operating system for pathology. (philips.com) (paige.ai)